1. Home
  2. USBC vs ANIX Comparison

USBC vs ANIX Comparison

Compare USBC & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USBC

USBC Inc.

HOLD

Current Price

$0.37

Market Cap

132.0M

Sector

N/A

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.45

Market Cap

119.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USBC
ANIX
Founded
1998
1982
Country
United States
United States
Employees
31
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.0M
119.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
USBC
ANIX
Price
$0.37
$3.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
167.5K
252.0K
Earning Date
05-08-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$2.32
52 Week High
$1.97
$5.46

Technical Indicators

Market Signals
Indicator
USBC
ANIX
Relative Strength Index (RSI) N/A 54.27
Support Level N/A $2.77
Resistance Level N/A $3.53
Average True Range (ATR) 0.00 0.25
MACD 0.00 -0.03
Stochastic Oscillator 0.00 20.00

Price Performance

Historical Comparison
USBC
ANIX

About USBC USBC Inc.

USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: